MedTrace Logo

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

NCT00831779 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2017-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity

Conditions

Interventions

DRUG

Dapagliflozin

Tablets, Oral, 5 mg, once daily, 12 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, Once daily, 12 weeks

Sponsors & Collaborators

  • Astra Zeneca, Bristol-Myers Squibb

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831779 on ClinicalTrials.gov